✦ LIBER ✦

e-antigen and age in acute and chronic type B hepatitis

✍ Scribed by Victor M. Villarejos; Kirsten Anderson Visona; Carlos E. Eduarte A.

Publisher: John Wiley and Sons
Year: 1978
Tongue: English
Weight: 496 KB
Volume: 2
Category: Article
ISSN: 0146-6615
DOI: 10.1002/jmv.1890020206

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Window Period Between Hepatitis B e

The Window Period Between Hepatitis B e Antigen and Antibody in Chronic Type B Hepatitis

✍ Yun-Fan Liaw; Miau-Ju Huang; Chia-Ming Chu; I-Shyan Sheen; Deng-Yn Lin 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 302 KB 👁 1 views

Age-specific prognosis following spontan

Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B

✍ Yi-Cheng Chen; Chia-Ming Chu; Yun-Fan Liaw 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 278 KB 👁 1 views

Hepatitis B e antigen (HBeAg) seroconversion in chronic hepatitis B virus infection confers a favorable prognosis, but untoward outcomes may develop in some patients. The impact of the age of HBeAg seroconversion on prognosis is not clearly known. HBeAg-positive patients with biopsy-proven chronic h

Hepatitis B e antigen–negative chronic h

Hepatitis B e antigen–negative chronic hepatitis b in Hong Kong

✍ Henry L. Y. Chan; Nancy W. Y. Leung; Munira Hussain; May L. Wong; Anna S. F. Lok 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

Hepatitis B e antigen-negative chronic hepatitis B (eϪCHB) has been reported in Asia but its prevalence and clinical significance have not been determined. The aims of this study were to determine the prevalence of eϪCHB in Hong Kong and the frequency of precore and core promoter mutations in these

Hepatitis B core antigen in serum during

Hepatitis B core antigen in serum during acute hepatitis B

✍ L. Chemello; P. Pontisso; E. Schiavon; V. Thiers; G. Tagariello; Dr. A. Albert 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 313 KB

Hepatitis B core antigen was measured in sera of patients with acute and chronic hepatitis B virus infection by a modified radioimmunoassay based on high molarity treatment of samples to avoid masking of antigen by homologous antibody. A good correlation between hepatitis B core antigen levels and s

Foscarnet therapy in chronic hepatitis B

Foscarnet therapy in chronic hepatitis B virus e antigen carriers

✍ V. G. Bain; H. M. Daniels; A. Chanas; G. J. M. Alexander; Dr. Roger Williams 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 343 KB 👁 2 views

Foscarnet (trisodium phosphonoformate) is a novel antiviral agent that inhibits viral-specific DNA polymerase. In the present study, eight males with chronic HBV carriage (HBeAg and HBV-DNA seropositivity >I2 months) showing chronic persistent hepatitis (CPH) or chronic active hepatitis (CAH) on liv

Age-specific prevalence and significance

Age-specific prevalence and significance of hepatitis B e antigen and antibody in chronic hepatitis B virus infection in taiwan: A comparison among asymptomatic carriers, Chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma

✍ Yun-Fan Liaw; Chia-Ming Chu; Deng-Yn Lin; I-Shyan Sheen; Chaur-Young Yang; Miau- 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 434 KB 👁 2 views

The age-specific prevalence of hepatitis B e antigen (HBeAg) and its antibody (anti-HBe) were studied by radioimmunoassay, and compared in a large series of patients with chronic hepatitis B virus (HBV) infection, including 268 asymptomatic carriers, 389 chronic hepatitis, 114 liver cirrhosis, and 2